NEWSROOM
Press Releases by Agendia
News
Press Releases
Agendia’s MammaPrint and BluePrint Tests Highlighted in Multiple Presentations at the 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility
Agendia will also host two additional educational opportunities for physicians and patient advocates during this year’s conference IRVINE, CA and AMSTERDAM – 2, December 2016 – Agendia, Inc., a world leader in personalized medicine and Read More
Agendia’s proven breast cancer recurrence assay, MammaPrint, now available in the Middle East
Agendia signs partnership agreement with Cryogene and Mist for Middle East distribution IRVINE, CA and AMSTERDAM, 8 November 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today a Read More
Agendia Announces the Award of a New Category 1 CPT Code from the American Medical Association for the MammaPrint 70-Gene Breast Cancer Recurrence Assay
The company also announces new patient awareness platform to help aid in breast cancer treatment decisions IRVINE, CA and AMSTERDAM – 1, November 2016 – Agendia, Inc., a world leader in personalized medicine and molecular Read More
Agendia Expands its Business Activities in Germany
The “BRIDGE” initiative offers German patients free access to Agendia’s MammaPrint® breast cancer recurrence assay Data from the MINDACT trial shows MammaPrint is the only test on the German market supported by the highest level Read More
Agendia appoints three leading cancer physicians to its Medical Advisory Board
IRVINE, CA and AMSTERDAM – 12 October 2016 – Agendia, Inc., a world leader in personalized medicine and molecular cancer diagnostics, announced today the appointment of three new members to its Medical Advisory Board. Prof. Read More
Agendia Responds to “Clinical Insights on MINDACT”
Dear Dr. Febbo, I recently received an email from you, in which you provided your unsolicited “Clinical Insights on MINDACT”. I have been a practicing medical oncologist for nearly 30 years, the last 20 Read More
New England Journal of Medicine Publishes MINDACT Trial Results Proving the Clinical Utility of MammaPrint in Assisting Physicians to Identify Early-Stage Breast Cancer Patients who can Safely Forgo Chemotherapy
46% of patients identified as high risk for recurrence according to clinical-pathological factors as described in the publication, and who therefore would be usual candidates for adjuvant chemotherapy, were reclassified as Low Risk by MammaPrint® Read More
